Fenton Mary Kay
SEC insider (Form 3/4/5 filer). CIK 0001378589. Chief Financial Officer at Cullinan Therapeutics, Inc. (CGEM). 5 reported Form 4/5 transactions since Sep 2024; latest on Jun 30, 2026. Located in CAMBRIDGE, MA.
Companies Fenton Mary Kay has filed insider reports for
- Cullinan Therapeutics, Inc. (CGEM): Officer, Chief Financial Officer
Fenton Mary Kay
CIK: 0001378589
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)1 (20.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)4 (80.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
CGEM
Cullinan Therapeutics, Inc.
Officer
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jun 30, 2026CGEM
Cullinan Therapeutics, Inc.
AwardDirect1.5K shares at avg. $8.60$13K - Feb 20, 2026CGEM
Cullinan Therapeutics, Inc.
SaleDirect4.4K shares at avg. $13.62$60K - Feb 18, 2026CGEM
Cullinan Therapeutics, Inc.
AwardDirect68.8K shares- - Dec 31, 2025CGEM
Cullinan Therapeutics, Inc.
AwardDirect27 shares at avg. $6.49$175.23 - Feb 19, 2025CGEM
Cullinan Therapeutics, Inc.
AwardDirect60K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 30, 2026 | CGEM Cullinan Therapeutics, Inc. | Award | 1,541 | $8.60 | $13,253 | Direct |
| Feb 20, 2026 | CGEM Cullinan Therapeutics, Inc. | Sale | 4,398 | $13.62 | $59,901 | Direct |
| Feb 18, 2026 | CGEM Cullinan Therapeutics, Inc. | Award | 68,750 | - | $0 | Direct |
| Dec 31, 2025 | CGEM Cullinan Therapeutics, Inc. | Award | 27 | $6.49 | $175 | Direct |
| Feb 19, 2025 | CGEM Cullinan Therapeutics, Inc. | Award | 60,000 | - | - | Direct |
1-5 of 5 transactions